Complement C3 and marginal zone B cells promote IgG-mediated enhancement of RBC alloimmunization in mice

Administration of anti-RhD immunoglobulin (Ig) to decrease maternal alloimmunization (antibody-mediated immune suppression [AMIS]) was a landmark clinical development. However, IgG has potent immune-stimulatory effects in other settings (antibody-mediated immune enhancement [AMIE]). The dominant thinking has been that IgG causes AMIS for antigens on RBCs but AMIE for soluble antigens. However, we have recently reported that IgG against RBC antigens can cause either AMIS or AMIE as a function of an IgG subclass. Recent advances in mechanistic understanding have demonstrated that RBC alloimmunization requires the IFN-α/-β receptor (IFNAR) and is inhibited by the complement C3 protein. Here, we demonstrate the opposite for AMIE of an RBC alloantigen (IFNAR is not required and C3 enhances). RBC clearance, C3 deposition, and antigen modulation all preceded AMIE, and both CD4+ T cells and marginal zone B cells were required. We detected no significant increase in antigen-specific germinal center B cells, consistent with other studies of RBC alloimmunization that show extrafollicular-like responses. To the best of our knowledge, these findings provide the first evidence of an RBC alloimmunization pathway which is IFNAR independent and C3 dependent, thus further advancing our understanding of RBCs as an immunogen and AMIE as a phenomenon.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:134

Enthalten in:

The Journal of clinical investigation - 134(2024), 8 vom: 15. Apr.

Sprache:

Englisch

Beteiligte Personen:

Jash, Arijita [VerfasserIn]
Pridmore, Thomas [VerfasserIn]
Collins, James B [VerfasserIn]
Hay, Ariel M [VerfasserIn]
Hudson, Krystalyn E [VerfasserIn]
Luckey, Chance John [VerfasserIn]
Zimring, James C [VerfasserIn]

Links:

Volltext

Themen:

Adaptive immunity
Complement C3
Immunoglobulin G
Immunology
Interferon-alpha
Journal Article

Anmerkungen:

Date Completed 16.04.2024

Date Revised 25.04.2024

published: Electronic

Citation Status MEDLINE

doi:

10.1172/JCI167665

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM371082927